<DOC>
	<DOCNO>NCT02350673</DOCNO>
	<brief_summary>This open-label , multi-center , Phase Ib clinical study cergutuzumab amunaleukin , combination atezolizumab , investigate safety , pharmacokinetics , therapeutic activity participant locally advance and/or metastatic carcinoembryonic antigen ( CEA ) -positive solid tumor , whose disease progress intolerant standard care therapy . Enrolled participant continue treatment treat loss clinical benefit , unacceptable toxicity , withdrawal consent . The study include 2 part : dose-escalation Part I dose expansion Part II . The anticipated treatment period 24 month cergutuzumab amunaleukin atezolizumab may modify emerge data suggest benefit .</brief_summary>
	<brief_title>A Study Intravenous ( IV ) Cergutuzumab Amunaleukin Atezolizumab Combination Participants With Locally Advanced and/or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Confirmed locally advance and/or metastatic solid tumor , least one tumor lesion noncritical location accessible biopsy ( exception nonsmall cell lung cancer [ NSCLC ] participant ) , confirm progression baseline progress , participant intolerant , standard care therapy Radiologically measurable clinically evaluable disease per RECIST v1.1 Life expectancy great equal ( &gt; /= ) 12 week Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 01 All acute toxic effect prior radiotherapy , chemotherapy , surgical procedure must resolve Grade le equal ( &lt; /= ) 1 , except alopecia ( grade ) Grade 2 peripheral neuropathy Adequate cardiac , hematological , liver renal function Negative serum pregnancy test within 7 day prior study treatment premenopausal woman woman &lt; /= 2 year menopause For woman postmenopausal undergone surgical sterilization : agreement remain abstinent use two adequate nonhormonal method contraception include least one method failure rate &lt; 1 % per year treatment period least five month last dose atezolizumab , 18 month last dose obinutuzumab , least four month last dose cergutuzumab amunaleukin , whichever long For men : agreement remain abstinent use contraceptive measure agreement refrain donate sperm Locally centrally confirm CEA expression archival tumor tissue Participants unilateral pleural effusion eligible inclusion fulfill GOLD classification 01 level pulmonary function New York Heart Association ( NYHA ) classification class 1 cardiac function Active untreated central nervous system ( CNS ) metastasis determine compute tomography ( CT ) magnetic resonance imaging ( MRI ) evaluation screen prior radiographic assessment ; participant history treat asymptomatic CNS metastasis eligible Spinal cord compression definitively treat surgery and/or radiation previously diagnose treat spinal cord compression without evidence disease clinically stable &gt; /= 2 week prior randomization Leptomeningeal disease Participants active second malignancy ( nonmelanoma skin cancer cervical carcinoma situ ) . Participants history malignancy consider active malignancy complete therapy consider treat physician &lt; /= 30 percent ( % ) risk relapse Evidence significant , uncontrolled concomitant disease could affect compliance protocol interpretation result , include diabetes mellitus , `` history relevant pulmonary disorder , know autoimmune diseases Participants bilateral pleural effusion NSCLC participant uni bilateral effusion confirm screen Xray eligible Uncontrolled hypertension , unstable angina , congestive heart failure ( CHF ) NYHA classification stage great ( &gt; ) 2 , serious cardiac arrhythmia require treatment ( exception : atrial fibrillation , paroxysmal supraventricular tachycardia ) , history myocardial infarction within 6 month enrollment Administration live , attenuate vaccine within 4 week Cycle 1 , Day 1 anticipation live attenuated vaccine require study . Influenza vaccination give influenza season . Participants must receive live , attenuate influenza vaccine within 4 week prior Cycle 1 , Day 1 , time study 5 month last dose atezolizumab Known Human Immunodeficiency Virus ( HIV ) Active hepatitis B ( HBV ) hepatitis C ( HCV ) infection . Participants positive hepatitis B surface antigen ( HBsAg ) Severe infection within 4 week prior Cycle 1 , Day 1 , include limited hospitalization complication infection , bacteremia , severe pneumonia Received oral intravenous ( IV ) antibiotic within 2 week prior Cycle 1 , Day 1 . Participants receive prophylactic antibiotic ( prevention urinary tract infection chronic obstructive pulmonary disease ) eligible Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition would contraindicate use investigational drug Major surgery significant traumatic injury le ( &lt; ) 28 day prior first cergutuzumab amunaleukin infusion ( exclude biopsy ) anticipation need major surgery study treatment Dementia alter mental status would prohibit informed consent History risk autoimmune disease , include limited systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjögren 's syndrome , Bell 's palsy , GuillainBarré syndrome , multiple sclerosis , vasculitis , glomerulonephritis Participants history autoimmune hypothyroidism stable dose thyroid replacement hormone participant control Type 1 diabetes mellitus stable insulin regimen may eligible study approval medical monitor Inclusion participant confirm positive serology least one autoantibody panel ( antinuclear antibody , antidouble strand deoxyribo nucleic acid [ DNA ] , cytoplasmic antineutrophil cytoplasmic antibody [ c ANCA ] , perinuclear antineutrophil cytoplasmic antibody [ p ANCA ] ) screen discuss Sponsor investigator , judge clinically relevant could refer specialist ( Rheumatologist ) exclude underlie autoimmune disease History idiopathic pulmonary fibrosis , pneumonitis ( include drug induce ) , organize pneumonia ( bronchiolitis obliterans , cryptogenic organize pneumonia ) , evidence active pneumonitis screen chest CT scan . History radiation pneumonitis radiation field ( fibrosis ) permit Baseline QTc interval &gt; 470 millisecond ( m ) , baseline rest bradycardia &lt; 45 beat per minute ( bpm ) , baseline rest tachycardia &gt; 100 bpm Pregnant breastfeeding woman Known hypersensitivity component obinutuzumab , cergutuzumab amunaleukin atezolizumab ; hypersensitivity Chinese hamster ovary cell product recombinant human antibody Investigational therapy within 28 day prior initiation study treatment Any approve anticancer therapy , include chemotherapy hormonal therapy , within 3 week prior initiation study treatment , exception state protocol Prior corticosteroid anticancer therapy within minimum 14 day first receipt study drug Last dose follow agent include limited : etanercept , infliximab , tacrolimus , cyclosporine , mycophenolic acid , alefacept , efalizumab &lt; 28 day prior first dose study drug Last dose prior immunotherapy include limited : interferon alpha ( IFNa ) , interferonbeta ( IFNß ) , interleukin ( IL ) 2 , conjugate IL2 , CEAIL2v , cytokine , antiCTLA4 , antiprogrammed deathligand 1 ( PDL1 ) , antiPD1 &lt; 28 day prior first cergutuzumab amunaleukin infusion History severe immunerelated adverse effect cergutuzumab amunaleukin ( CEAIL2v ) antiPD1 ( nivolumab , pembrolizumab ) antiPDL1 ( atezolizumab ) therapy ( Common Terminology Criteria Adverse Events [ CTCAE ] Grade 3 4 ) The eligibility participant know develop previous treatment antidrug antibody ( ADAs ) cergutuzumab amunaleukin ( CEAIL2v ) discuss Sponsor Regular immunosuppressive therapy Treatment systemic immunosuppressive medication include , limited : prednisone , cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor ( TNF ) agent within 2 week prior Cycle 1 , Day 1 . Participants receive acute and/or lowdose systemic immunosuppressant medication may enrol study discussion approval Medical Monitor . The use inhale corticosteroid mineralocorticoid participant orthostatic hypotension adrenocortical insufficiency allow Radiotherapy within last 4 week start study drug treatment exception limit field palliative radiotherapy bone pain relief History progressive multifocal leukoencephalopathy ( PML )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>